Next Gen’s NGD Infection Prevention to come into force from 1st January 2026

Announcement

Next Gen Diagnostics announced the exciting offshoot of its Infection Prevention division into an independent and strong-headed company from 1st January 2026. The company will be called as NGD Infection Prevention aimed on the execution of real-time, on-point genomic transmission detection throughout U.S. hospitals. This shift is aligned with the vast recognition stating that the sequencing of infection has turned into a practical space to address and avoid transmission in hospitals and balance the incorporated human and financial costs.

A jump to implementation

CEO of Next Gen Diagnostics, Dr Paul A. Rhodes, said, “The field has reached its advanced time. The potential needed to allow vast adaptability of sequence-related transmission detection with briefed automated bioinformatics and sequencing, and affordability, has come under one roof. It's similar, recognising that most of the transmissions seen in hospitals are avoided by previous methods. There are practical pathways to execute this service in hospitals, and so we are installing the first systems in Israel and the US.”

In the last few years, the peer-reviewed studies spotted the negligence towards detecting transmission by skilled and enthusiastic Infection Prevention teams. It was also unaddressed at the places that were supposed to be safe, such as neonatal intensive care units. But now the recent work has illustrated that implementing sequencing to capture transmission can record the effective intervention.

Director of Strategic Partnerships for NGD Infection Prevention, Samantha Kahn, said, “We will be announcing in the new year at the concert with a publication being dictated for submission that will measure the impact of sequence-related detection that’s seen in a hospital with the accelerated degree of antibiotic-resistant infection. It also shows mitigation in the average length of stay and the prevention of negative human outcomes involving mortality.”

Further, Dr Rhodes clearly explained in a statement saying, “NGD Infection Prevention was built to increase the number of deliveries of sequence-related transmission detection. The technology development is not the major challenge, but the focus on successful deployment, exemplary backing and communication with customers is fundamental. Following this, the deliverables will maintain scalability to serve services to any of the 16,000 nursing homes, 7,000 dialysis centers and 7,300 hospitals in the United States.”

“The prevention of adverse patient events, financial savings and mitigation of average length of stay are fascinating to meet excellence before this practice that’s reimbursed by payers and empowering. But incentivised or mandated by regulators as they address, there is a practical way to avoid recent undetected transmission. NGD Infection Prevention was constructed to meet this need.”